Uncategorized – Talk Bio

Novartis and Relation Therapeutics form AI-driven, multi-program atopic disease collaboration

22 hours ago talkbio0Tagged * * atopic diseases * *, * * functional cell, AI-powered, Asthma, atlases, Billion, Drug Discovery, Eczema, Hypersensitivity, IL13 gene, immuno-dermatology, Lab-in-the-Loop, milestones, multi-program collaboration, Novartis

Novartis; Relation Therapeutics; AI-powered drug discovery; Lab-in-the-Loop; atopic diseases; immuno-dermatology; multi-program collaboration; asthma; allergies; eczema; allergic rhinitis; $55 million upfront; $1.7 billion milestones; functional cell atlases

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

1 day ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, BREAST-01, disease control rate, Gene Expression, Myers Squibb, ORR, PD-L1, PD-L1xVEGF-A, Phase 2 trial, Progression-Free Survival, pumitamig, ROSETTA, SABCS, TNBC, Triple Negative Breast Neoplasms

BioNTech; Bristol Myers Squibb; pumitamig; BNT327; PD-L1xVEGF-A bispecific antibody; Phase 2 trial; triple-negative breast cancer; TNBC; confirmed ORR; disease control rate; progression-free survival; PD-L1 expression; ROSETTA BREAST-01; SABCS

GSK walks away from remaining IDEAYA programs, formally ending partnership

1 day ago talkbio0Tagged Collaboration termination, DNA Repair, drug development pipeline, Ideaya Biosciences, License Agreement, oncology partnership, Pol Theta, SmithKline Beecham, Synthetic Lethality, Werner helicase

GSK; IDEAYA Biosciences; synthetic lethality; collaboration termination; Werner helicase; Pol Theta; DNA damage repair; oncology partnership; license agreement; drug development pipeline

Merck to Acquire Cidara Therapeutics for $9.2 Billion

1 day ago talkbio0Tagged Acquisition, Antiviral Agents, Breakthrough Therapy Designation, CD388, Cidara Therapeutics, Immunostimulating conjugate (antigen), influenza prevention, Merck

Merck; Cidara Therapeutics; acquisition; $9.2 billion; CD388; influenza prevention; antiviral; drug-Fc conjugate; Breakthrough Therapy Designation; Keytruda

Wave Life Sciences RNA obesity shot shows fat loss with muscle preservation but trails Eli Lilly’s candidates

1 day ago talkbio0Tagged Adangme language, eli lilly, fat loss, INHBE, Injection of therapeutic agent, muscle preservation, Obesity, RNA obesity, Scientific Sessions, Wave Life Sciences, WVE-007

Wave Life Sciences; WVE-007; INHBE; RNA obesity drug; obesity shot; fat loss; muscle preservation; Eli Lilly; ADA Scientific Sessions

Dyne Therapeutics Reports Positive Results for Duchenne Drug DYNE-251, Plans FDA Approval Submission

1 day ago talkbio0Tagged Accelerated, Approved, Biological Factors, Breakthrough Therapy Designation, Clinical Trials, DELIVER (veterinary product), Dyne Therapeutics, DYNE-251, License Application, Muscular Dystrophy, Duchenne, United States Food and Drug Administration

Dyne Therapeutics; DYNE-251; Duchenne muscular dystrophy; exon 51 skipping; DELIVER trial; FDA Breakthrough Therapy Designation; Biologics License Application; accelerated approval

Bruker Adds Diagnostics Leader Jack Phillips to Board of Directors Effective January 2026

2 days ago talkbio0Tagged Accelerate Diagnostics, Appointments, board of directors, Bruker Corporation, Corporate governance, diagnostics industry, Jack Phillips, Roche Diagnostics North America, Ventana Medical Systems * *

Bruker Corporation; Jack Phillips; Board of Directors; appointment; January 1 2026; diagnostics industry; corporate governance; Accelerate Diagnostics; Roche Diagnostics North America; Ventana Medical Systems

Astrin Biosciences Announces Scientific Advisory Board to Advance Early Cancer Detection Leveraging AI and Proteomics

2 days ago talkbio0Tagged Astrin Biosciences, cancer intelligence, Detection, Liquid Biopsy, Proteomics, Scientific Advisory Board

Astrin Biosciences; Scientific Advisory Board; early cancer detection; AI; proteomics; liquid biopsy; cancer intelligence

Biotech interest shifting from obesity ‘halo’ to other areas like oncology and blood cancers

2 days ago talkbio0Tagged Autoimmune, biotech pivot, Halo brace, Investments, leukemia, Neoplasms, Novartis, Obesity, sector rotation

obesity drugs; biotech pivot; investment trends; Novartis; leukemia; obesity halo; sector rotation; autoimmune; oncology

FDA Signals Higher Efficacy Bar for New CAR‑T Cancer Therapies

2 days ago talkbio0Tagged CAR-T, Cells, Chimeric Antigen Receptor T-Cell Therapy, gene therapy, Hematologic Neoplasms, Neoplasms, Overall Survival, Randomized Controlled Trials as Topic, regulatory standards, superiority trials, United States Food and Drug Administration

FDA; CAR-T; chimeric antigen receptor T-cell therapy; oncology; regulatory standards; superiority trials; randomized controlled trials; overall survival; hematologic malignancies; cell and gene therapy